Skip to content
OpenCapital
Get started

Eli Lilly LLY Trulicity — Revenue

Other product segments

Mounjaro
$8.66B+125%
Zepbound
$4.16B+79.9%
Verzenio
$1.3B+12.3%
Jardiance
$1.11B+9.9%
Other oncology
$966M+22.4%
Other cardiometabolic health
$905M-4.2%
Taltz
$733M-3.8%
Other immunology
$470M+44.2%
Neuroscience
$382M+40.4%

Similar metrics at other companies

Cumberland Pharmaceuticals logo
CPIXTalicia — Revenue
$1.92M—
Amgen logo
AMGNUPLIZNA — Total revenues
$262M+188%
Incyte logo
INCYICLUSIG — Total revenues
$35.46M+20.0%
Aurinia Pharmaceuticals logo
AUPHU.S. — Revenue
$65.96M+25.6%
Supernus Pharmaceuticals logo
SUPNTrokendi XR — Total revenues
$9.48M-26.0%
Ardelyx logo
ARDXUnited States — Total revenues
$94.45M+18.4%

Other financials

Income statement

See full
Revenue$19.8B+55.5%
Gross profit$16.2B+54.4%
Net income$7.4B+168%
EPS (diluted)$8.26+170%

Balance sheet

See full
Cash & equivalents$5.3B+70.8%
Total debt$43.4B+12.6%
Total equity$31.2B+97.9%
Total assets$116.58B+30.4%

Cash flow

See full
Operating cash flow$5.3B+220%
CapEx$2.3B+54.0%
Free cash flow$3.0B+1,828%

Valuation

See full
Market cap$1.09T+56.4%
Enterprise value$1.12T+53.8%
P/E42.9×-7.3×
P/S15×+2.0×

Profitability

See full
Gross margin82.8%+1.1pp
Net margin35%+12.3pp
FCF margin16.4%+8.7pp

Returns & leverage

See full
Return on equity107.6%+29.9pp
Debt / equity1.4×-1.1×
Current ratio1.5×+0.1×

Where this comes from

Reported directly by Eli Lilly in its filing.

Tagged under the XBRL concept us-gaap:Revenues.

The official record: Eli Lilly’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Eli Lilly's trulicity — revenue.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Eli Lilly's trulicity — revenue?
Eli Lilly (LLY) reported trulicity — revenue of $919M in Q1 2026.
How has Eli Lilly's trulicity — revenue changed year-over-year?
Eli Lilly's trulicity — revenue decreased by 16.1% year-over-year, from $1.1B to $919M.
What is the long-term trend for Eli Lilly's trulicity — revenue?
Over 4 years (2021 to 2025), Eli Lilly's trulicity — revenue has grown at a -9.8% compound annual growth rate (CAGR), from $6.47B to $4.28B.
What does trulicity — revenue mean?
This metric represents the total net sales generated by the Trulicity product line, a glucagon-like peptide-1 (GLP-1) receptor agonist used for the treatment of type 2 diabetes. It reflects the commercial performance and market adoption of this specific therapeutic asset within the company's cardiometabolic portfolio. Tracking this revenue stream is essential for assessing the product's lifecycle stage, competitive positioning against newer GLP-1 therapies, and its contribution to overall pharmaceutical segment growth.